Bahnemann R. , Jacobs M., Karbe E., Kaufmann W., Morawietz G., Nolte T., Rittinghausen S. (1995). RITA—Registry of industrial toxicology animal-data. Guides for organ sampling and trimming procedures in rats. Exp Toxicol Pathol47: 247-266.
2.
Boorman GA, Montgomery CA Jr, Eustis SL, Wolfe MJ, McConnell EE, Hardisty JF (1985). Quality assurance in pathology for rodent carcinogenicity studies. In: Handbook ofCarcinogen Testing, Milman HA, Weisburger EK (eds). Noyes Publications, NewJersey, pp 345-357.
3.
Chhabra RS, Huff JE, Schwetz BS, Selkirk J. (1990). An overview of prechronic and chronic toxicity/carcinogenicity experimental study design and criteria used by the National Toxicology Program . Environ Health Perspect86: 313-321.
4.
Contrera JF, Jacobs AC, DeGeorge JJ (1997). Carcinogenicity and the evaluation of regulatory requirements for pharmaceuticals. Regul Toxicol Pharmacol25: 130-145.
5.
Devor DE, Henneman JR, Kurata Y., Rehm S., Weghorst CM, Ward JM ( 1994). Pathology procedures in laboratory animal carcinogenesis studies. In: Carcinogenesis, Waalkes MP, Ward JM (eds). Raven Press, New York, pp 429-466.
6.
Dua PN, Jackson BA (1988). Review of pathology data for regulatory purposes . Toxicol Pathol16: 443-450.
7.
European Community Commission (1989). Note for guidance concerning the application of chapter I (E) of Part 2 of the Annex to Directive 75/318/EEC, with a View to the Granting of a Marketing Authorization of a New Drug, pp 107-112.
8.
Faccini JM, Butler WR, Friedmann JC, Hess R., Reznik GK, Ito N., Hayashi Y., Williams GM (1992). IFSTP guidelines for the design and interpretation of the chronic rodent carcinogenicity bioassay. Exp Toxicol Pathol44: 443-456.
9.
Frith CH, Boothe AD, Greenmann DL, Farmer JH (1979). Correlations between gross and microscopic lesions in carcinogenic studies in mice. J Environ Pathol Toxicol3: 139-153.
10.
Gold LS, Zeiger E. (1997). Carcinogenic Potency and Genotoxicity Databases . CRC Press, New York.
11.
Greaves P. (1990). Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation. Elsevier, Amsterdam.
Haseman JK, Boorman GA, Huff J. ( 1997). Value of historical control data and other issues related to the evaluation of long-term rodent carcinogenicity studies. Toxicol Pathol20: 524-527.
14.
Haseman JK, Hailey JR, Morris RW (1998). Spontaneous neoplasm incidences in Fisher 344 rats and B6C3F mice in two-year carcinogenicity studies: A National Toxicology Program update. Toxicol Pathol26: 428-441.
15.
Haseman JK, Huff JE, Rao GN, Eustis SL (1989). Sources of variability in rodent carcinogenicity studies. Fundam Appl Toxicol12: 793-804.
16.
International Conference on Harmonisation. Guidelines S1A, S1B, S1C, S1C(R). In: Proceedings of the Fourth International Conference on Harmonisation, 1997: Brussels , Belgium, D'Arcy PF, Harron DWG (eds). Queen's University Press, Belfast, pp 941-970. 17. Japanese Ministry of Health and Welfare (1997 ). Pharmaceutical and Medical Safety Bureau. In: Guidelines for Toxicity Studies of Drugs. Yakuji Nippo , Tokyo, pp 147-175.
17.
Kulwich BA, Hardisty JF, Gilmore CE, Ward JM ( 1980). Correlation between gross obversations of tumors and neoplasms diagnosed microscopically in carcinogenesis bioassays in rats. J Environ Pathol Toxicol3: 281-287.
18.
Long PH, Elwell M., Harris RK, Leininger JR, McKinney LA, Moch RW, Slayter MV (1992). Guides for toxicologic pathology. In: Standardized System of Nomenclature and Diagnostic Criteria. STP/ARP / AFIP, Washington, DC, p 3.
19.
Maronpot RR (1991). Chemical carcinogenesis. In: Handbook of Toxicologic Pathology, Haschek WM, Rousseaux CG (eds). Academic Press, San Diego, pp 91-129.
20.
McConnell EE (1983). Pathology requirements for two-year rodent studies. I—A review of current procedures. Toxicol Pathol11: 60-64.
21.
McConnell EE (1983). Pathology requirements for two-year rodent studies. II—Alternative approaches. Toxicol Pathol11: 65-76.
22.
Mohr U., Capen CC, Dungworth DL, Griesemer RA, Ito N., Turusov VS (1992-1993). International classification of rodent tumours part I—The rat. IARC Scientific Publication No 122, Lyon , France.
23.
Monro AM (1996). Are lifespan rodent carcinogenicity studies defensible for pharmaceutical agents?Exp Toxicol Pathol48: 155-166.
24.
Monro AM, MacDonald JS (1998). Evaluation of the carcinogenic potential of pharmaceuticals . Opportunities arising from the International Conference on Harmonisation. Drug Safety 18: 309-319.
25.
Organization for Economic Cooperation and Development (1993). Guidelines for testing of chemicals, section 4—Health effects. Carcinogenicity Studies 451 . Publications Service, OECD, Paris.
26.
Physicians Desk Reference (1999). Medical Economics Company, Montvale, New Jersey.
27.
Robens JF, Calabrese EJ, Piegorsch WW, Schueler RL, Hayes AW (1994). Principles of testing for carcinogenicity. In: Principles and Methods of Toxicology, Hayes AW (ed). Raven Press, New York, pp 697-728.
28.
Society of Toxicologic Pathologists (1997). Documentation of pathology peer review. Toxicol Pathol25: 655.
29.
Sontag JM, Page NP, Saffiotti U. (1976). Guidelines for Carcinogen Bioassay in Small Rodents . NCI-CG-TR-1, DHEW (NIH) 76-801, National Cancer Institute, Bethesda, Maryland.
30.
Soule NW (1987). Gut rolls: A better technique for GI tumor assessment . Toxicol Pathol15: 374.
31.
Squire R. (1989). The interpretation of equivocal or marginal animal carcinogenic tests. Cell Biol Toxicol5: 371-376.
32.
Thompson SW , Hunt RD (1963). Spontaneous tumors in the Sprague-Dawley rat. Ann NY Acad Sci108: 832-845.
33.
US Environmental Protection Agency (1989). Health effects test guidelines. Pesticides and Toxic Substances (H-7504C). Subdivision F Guideline Ref 83-2. EPA 560/09-90-078, Washington, DC.
34.
US Food and Drug Administration. Bureau of Foods (1982). Toxicological principles for the safety assessment of direct food additives and color additives used in food. National Technical Information Service, Springfield, Virginia.
35.
US Food and Drug Administration. Bureau of Foods (Draft revision1996). Toxicological principles for the safety assessment of direct food additives and color additives used in food.
36.
van Oosterhout Jpj, van Der Laan JW, De Waal EJ, Olejniczak K., Hilgenfeld M., Schmidt V., Bass R. (1997). The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul Toxicol Pharmacol25: 6-17.
37.
Ward JM (1983). Background data and variations in tumor rates of control rats and mice. Prog Exp Tumor Res26: 241-258.
38.
Ward JM, Reznik G. (1983). Refinements of rodent pathology and the pathologist's contribution to evaluation of carcinogenesis bioassays. Prog Exp Tumor Res26: 266-291.
39.
Weisburger JH , Weisburger EK (1967). Tests for chemical carcinogens . In: Methods in Cancer Research, Busch H (ed). Academic Press , New York, pp 307-387.
40.
Woutersen RA , van Garderen-Hoetmer A., Slootweg PJ, Feron VJ (1994). Upper respiratory tract carcinogenesis in experimental animals and in humans . In: Carcinogenesis, Waalkes MP, Ward JM (eds). Raven Press, New York, pp 215-264.